EICHORCondition: Inflammatory Bowel Diseases · Ulcerative Colitis · Crohn Disease · Sponsor: Seoul National University Bundang Hospital
Interested? Contact the study team ↓
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
A study of clinical characteristics and potential prognostic factors in inflammatory bowel disease
This description comes directly from the study's public registry record.
Yu kyung Jun, M.D., Ph.D · + 82-31-787-7845 · juk0220@nate.com
There is no obligation to join — the study team can answer your questions about taking part.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: * control group: Patients who do not have colitis, cancer, and advanced polyp (the number of polyps ≥ 3, the size of polyps ≥ 1cm, high-grade adenoma, villous adenoma) * TNF-α inhibitor-naive IBD group: IBD patients who do not have a history of TNF-α inhibitor treatment * TNF-α inhibitor-treated IBD group: IBD patients who are treated with TNF-α inhibitor Exclusion Criteria: * Age under 18 years * Patients who were treated with antibiotics or probiotics within the last 3 months
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| Seoul National University Bundang Hospital | Seongnam-si, Gyeonggi-do, South Korea | Recruiting |
This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05653011